Glaukos (GKOS) Stock Forecast & Price Target

Compare

372 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GKOS Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Glaukos

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GKOS Stock 12 Month Forecast

Average Price Target

$115.33

▲(45.12% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $115.33 with a high forecast of $165.00 and a low forecast of $86.00. The average price target represents a 45.12% change from the last price of $79.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"82":"$82","103":"$103","124":"$124","145":"$145","166":"$166"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$165.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$115.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$86.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[82,103,124,145,166],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.19,89.48307692307692,95.77615384615385,102.06923076923077,108.3623076923077,114.65538461538462,120.94846153846154,127.24153846153845,133.5346153846154,139.8276923076923,146.12076923076924,152.41384615384615,158.7069230769231,{"y":165,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.19,85.66230769230769,88.13461538461539,90.60692307692307,93.07923076923076,95.55153846153846,98.02384615384615,100.49615384615385,102.96846153846154,105.44076923076923,107.91307692307691,110.38538461538461,112.8576923076923,{"y":115.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.19,83.40615384615384,83.62230769230769,83.83846153846153,84.05461538461539,84.27076923076923,84.48692307692308,84.70307692307692,84.91923076923077,85.13538461538461,85.35153846153847,85.56769230769231,85.78384615384616,{"y":86,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":126.55,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.77,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.44,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.54,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$165.00

Average Price Target$115.33

Lowest Price Target$86.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Newitter

Truist Financial

―

Buy

―

Reiterated

10/21/25

Truist Financial Sticks to Their Buy Rating for Glaukos (GKOS)

Lila Implantra

TR | OpenAI - 4o

$86→$78

Hold

-1.85%

Downside

Reiterated

10/21/25

AI Generated ArticleAI Generated Article

Ryan Zimmerman

BTIG

$104

Buy

30.87%

Upside

Reiterated

10/20/25

Analysts' Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Glaukos (GKOS)We get an agenda ahead of the meeting, we listen to see what they say, and we wait...until an LCD is proposed. Beyond that there could be various iterations around usage frequency, minimum requirements for treatment before coverage, and various other factors that could impact demand. We do not expect, and some investors have asked, a change in pricing or reimbursement to the product (as we have not seen any evidence of this in other LCDs in the past).

Thomas Stephan

Stifel Nicolaus

$115

Buy

44.71%

Upside

Reiterated

10/08/25

Stifel Nicolaus Remains a Buy on Glaukos (GKOS)Stifel analyst Thomas Stephan reiterated a Buy rating and $115.00 price target on Glaukos Corporation (NYSE: GKOS).

Joanne Wuensch

Citi

$140→$110

Buy

38.42%

Upside

Reiterated

10/07/25

Glaukos price target lowered to $110 from $140 at CitiGlaukos price target lowered to $110 from $140 at Citi

David Roman

Goldman Sachs

$103

Buy

29.61%

Upside

Initiated

10/01/25

Glaukos initiated with a Buy at Goldman SachsGlaukos initiated with a Buy at Goldman Sachs

Adam Maeder

Piper Sandler

$165

Buy

107.63%

Upside

Reiterated

09/29/25

Glaukos (GKOS) Receives a Buy from Piper Sandler

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/27/25

William Blair Keeps Their Buy Rating on Glaukos (GKOS)

Larry Biegelsen

Wells Fargo

$92

Hold

15.77%

Upside

Reiterated

08/12/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Glaukos (NYSE: GKOS)

Anthony Petrone

Mizuho Securities

$150→$130

Buy

63.58%

Upside

Reiterated

07/31/25

Glaukos price target lowered to $130 from $150 at MizuhoGlaukos price target lowered to $130 from $150 at Mizuho

Danielle Antalffy

UBS

$125→$134

Buy

68.62%

Upside

Reiterated

07/31/25

Glaukos Corporation (GKOS) PT Raised to $134 at UBSUBS analyst Danielle Antalffy raised the price target on Glaukos Corporation (NYSE: GKOS) to $134.00 (from $125.00) while maintaining a Buy rating.

Allen Gong

J.P. Morgan

$100→$110

Buy

38.42%

Upside

Reiterated

07/31/25

J.P. Morgan Sticks to Their Buy Rating for Glaukos (GKOS)JPMorgan analyst Allen Gong raised the price target on Glaukos Corporation (NYSE: GKOS) to $110.00 (from $100.00) while maintaining a Overweight rating.

David Saxon

Needham

$115

Buy

44.71%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and Glaukos (NYSE: GKOS)

Michael Sarcone

Jefferies

$160

Buy

101.33%

Upside

Assigned

06/04/25

Promising Outlook for Glaukos: Strategic Advancements and Market Growth Drive Buy Rating

Mason Carrico

Stephens

$140→$115

Buy

44.71%

Upside

Reiterated

05/02/25

Glaukos price target lowered to $115 from $140 at StephensGlaukos price target lowered to $115 from $140 at Stephens

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Newitter

Truist Financial

―

Buy

―

Reiterated

10/21/25

Truist Financial Sticks to Their Buy Rating for Glaukos (GKOS)

Lila Implantra

TR | OpenAI - 4o

$86→$78

Hold

-1.85%

Downside

Reiterated

10/21/25

AI Generated ArticleAI Generated Article

Ryan Zimmerman

BTIG

$104

Buy

30.87%

Upside

Reiterated

10/20/25

Thomas Stephan

Stifel Nicolaus

$115

Buy

44.71%

Upside

Reiterated

10/08/25

Stifel Nicolaus Remains a Buy on Glaukos (GKOS)Stifel analyst Thomas Stephan reiterated a Buy rating and $115.00 price target on Glaukos Corporation (NYSE: GKOS).

Joanne Wuensch

Citi

$140→$110

Buy

38.42%

Upside

Reiterated

10/07/25

Glaukos price target lowered to $110 from $140 at CitiGlaukos price target lowered to $110 from $140 at Citi

David Roman

Goldman Sachs

$103

Buy

29.61%

Upside

Initiated

10/01/25

Glaukos initiated with a Buy at Goldman SachsGlaukos initiated with a Buy at Goldman Sachs

Adam Maeder

Piper Sandler

$165

Buy

107.63%

Upside

Reiterated

09/29/25

Glaukos (GKOS) Receives a Buy from Piper Sandler

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/27/25

William Blair Keeps Their Buy Rating on Glaukos (GKOS)

Larry Biegelsen

Wells Fargo

$92

Hold

15.77%

Upside

Reiterated

08/12/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Glaukos (NYSE: GKOS)

Anthony Petrone

Mizuho Securities

$150→$130

Buy

63.58%

Upside

Reiterated

07/31/25

Glaukos price target lowered to $130 from $150 at MizuhoGlaukos price target lowered to $130 from $150 at Mizuho

Danielle Antalffy

UBS

$125→$134

Buy

68.62%

Upside

Reiterated

07/31/25

Glaukos Corporation (GKOS) PT Raised to $134 at UBSUBS analyst Danielle Antalffy raised the price target on Glaukos Corporation (NYSE: GKOS) to $134.00 (from $125.00) while maintaining a Buy rating.

Allen Gong

J.P. Morgan

$100→$110

Buy

38.42%

Upside

Reiterated

07/31/25

David Saxon

Needham

$115

Buy

44.71%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and Glaukos (NYSE: GKOS)

Michael Sarcone

Jefferies

$160

Buy

101.33%

Upside

Assigned

06/04/25

Promising Outlook for Glaukos: Strategic Advancements and Market Growth Drive Buy Rating

Mason Carrico

Stephens

$140→$115

Buy

44.71%

Upside

Reiterated

05/02/25

Glaukos price target lowered to $115 from $140 at StephensGlaukos price target lowered to $115 from $140 at Stephens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Glaukos

1 Month

xxx

Success Rate

10/11 ratings generated profit

Average Return

+6.76%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 90.91% of your transactions generating a profit, with an average return of +6.76% per trade.

3 Months

xxx

Success Rate

9/11 ratings generated profit

Average Return

+3.94%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +3.94% per trade.

1 Year

David SaxonNeedham

Success Rate

12/17 ratings generated profit

Average Return

+35.28%

reiterated a buy rating 3 months ago

Copying David Saxon's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +35.28% per trade.

2 Years

xxx

Success Rate

9/15 ratings generated profit

Average Return

+23.18%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +23.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GKOS Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GKOS has received 11 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. GKOS average Analyst price target in the past 3 months is 115.33.

Each month's total comprises the sum of three months' worth of ratings.

GKOS Financial Forecast

GKOS Earnings Forecast

Next quarter’s earnings estimate for GKOS is -$0.26 with a range of -$0.31 to -$0.20. The previous quarter’s EPS was -$0.24. GKOS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year GKOS has Preformed in-line its overall industry.

GKOS Sales Forecast

Next quarter’s sales forecast for GKOS is $122.44M with a range of $121.00M to $124.18M. The previous quarter’s sales results were $124.12M. GKOS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year GKOS has Preformed in-line its overall industry.

GKOS Stock Forecast FAQ

What is GKOS’s average 12-month price target, according to analysts?

Based on analyst ratings, Glaukos’s 12-month average price target is 115.33.

What is GKOS’s upside potential, based on the analysts’ average price target?

Glaukos has 45.12% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GKOS a Buy, Sell or Hold?

Glaukos has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is Glaukos’s price target?

The average price target for Glaukos is 115.33. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $165.00 ,the lowest forecast is $86.00. The average price target represents 45.12% Increase from the current price of $79.47.

What do analysts say about Glaukos?

Glaukos’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of GKOS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Glaukos (GKOS) Stock Forecast & Price Target

GKOS Analyst Ratings

GKOS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Glaukos

GKOS Analyst Recommendation Trends

GKOS Financial Forecast

GKOS Earnings Forecast

GKOS Sales Forecast

GKOS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts